DK3386541T3 - Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab - Google Patents
Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab Download PDFInfo
- Publication number
- DK3386541T3 DK3386541T3 DK16818985.0T DK16818985T DK3386541T3 DK 3386541 T3 DK3386541 T3 DK 3386541T3 DK 16818985 T DK16818985 T DK 16818985T DK 3386541 T3 DK3386541 T3 DK 3386541T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical formulation
- aqueous pharmaceutical
- including anti
- formulation including
- antibody avelumab
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15198233 | 2015-12-07 | ||
| PCT/EP2016/002040 WO2017097407A1 (en) | 2015-12-07 | 2016-12-05 | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3386541T3 true DK3386541T3 (da) | 2020-09-28 |
Family
ID=54838201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16818985.0T DK3386541T3 (da) | 2015-12-07 | 2016-12-05 | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US11058769B2 (da) |
| EP (2) | EP3386541B1 (da) |
| JP (1) | JP6925337B2 (da) |
| KR (1) | KR102697026B1 (da) |
| CN (1) | CN108367072B (da) |
| AR (1) | AR107014A1 (da) |
| AU (1) | AU2016368099C1 (da) |
| CA (1) | CA3007481C (da) |
| CL (1) | CL2018001488A1 (da) |
| CO (1) | CO2018005525A2 (da) |
| CY (1) | CY1123358T1 (da) |
| DK (1) | DK3386541T3 (da) |
| EA (1) | EA201891339A1 (da) |
| ES (1) | ES2823279T3 (da) |
| HR (1) | HRP20201573T1 (da) |
| HU (1) | HUE050811T2 (da) |
| IL (1) | IL259563B (da) |
| LT (1) | LT3386541T (da) |
| MX (1) | MX389289B (da) |
| MY (1) | MY195681A (da) |
| NZ (1) | NZ743964A (da) |
| PE (1) | PE20181400A1 (da) |
| PH (1) | PH12018500894A1 (da) |
| PL (1) | PL3386541T3 (da) |
| PT (1) | PT3386541T (da) |
| RS (1) | RS61029B1 (da) |
| SA (1) | SA518391743B1 (da) |
| SG (1) | SG11201804758QA (da) |
| SI (1) | SI3386541T1 (da) |
| SM (1) | SMT202000497T1 (da) |
| TW (1) | TWI630917B (da) |
| UA (1) | UA123270C2 (da) |
| WO (1) | WO2017097407A1 (da) |
| ZA (1) | ZA201804534B (da) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101981873B1 (ko) * | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| AU2016233495B2 (en) | 2015-03-13 | 2022-02-24 | Cytomx Therapeutics, Inc | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
| DK3386541T3 (da) | 2015-12-07 | 2020-09-28 | Merck Patent Gmbh | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab |
| JP6730466B2 (ja) | 2016-06-13 | 2020-07-29 | アイ−エムエービー バイオファーマ ユーエス リミテッド | 抗ｐｄ−ｌ１抗体およびその使用 |
| AU2017339856B2 (en) | 2016-10-06 | 2024-09-05 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| WO2018162446A1 (en) * | 2017-03-06 | 2018-09-13 | Merck Patent Gmbh | Aqueous anti-pd-l1 antibody formulation |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| WO2019085982A1 (zh) * | 2017-11-02 | 2019-05-09 | 正大天晴药业集团南京顺欣制药有限公司 | 一种抗pd-l1人源化单克隆抗体的药物组合物 |
| JP7692699B2 (ja) * | 2017-12-22 | 2025-06-16 | サムスン バイオエピス カンパニー リミテッド | Ｖｅｇｆアンタゴニストを含む液体組成物 |
| US20210079106A1 (en) * | 2017-12-28 | 2021-03-18 | Julius-Maximilians-Universität Würzburg | TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA) |
| WO2020020307A1 (en) | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| WO2020060183A1 (ko) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | 트라스투주맙 항체 안정화 액체 제제 |
| KR20210096640A (ko) * | 2018-11-29 | 2021-08-05 | 하버 바이오메드 테라푸틱스 리미티드 | 항-pd-l1 항체 제제 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| CA3144244A1 (en) * | 2019-06-25 | 2020-12-30 | Innovent Biologics (Suzhou) Co., Ltd. | Formulation comprising anti-cd47/pd-l1 bispecific antibody, method for preparing same and use thereof |
| CN111420049A (zh) * | 2019-08-22 | 2020-07-17 | Biocad股份公司 | 抗-pd1抗体prolgolimab的水性药物组合物及其应用 |
| TW202535466A (zh) | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| US12121565B2 (en) | 2019-09-13 | 2024-10-22 | Duke University | Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies |
| US12380963B2 (en) | 2019-10-14 | 2025-08-05 | The Medical College Of Wisconsin, Inc. | Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy |
| WO2021087105A1 (en) | 2019-10-30 | 2021-05-06 | Duke University | Immunotherapy with combination therapy comprising an immunotoxin |
| EP4055153A4 (en) | 2019-11-04 | 2024-02-14 | Duke University | TREATMENT OF PRIMARY AND METASTASIC CANCER |
| KR20220115803A (ko) * | 2019-12-13 | 2022-08-18 | 삼성바이오에피스 주식회사 | 안정한 항-pd-1 항체 약제학적 제제 |
| CA3164600A1 (en) * | 2019-12-18 | 2021-06-24 | Tesaro, Inc. | Biopharmaceutical compositions and related methods |
| KR102683876B1 (ko) * | 2020-11-11 | 2024-07-11 | 가톨릭대학교 산학협력단 | 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트 |
| EP4362984A1 (en) | 2021-07-02 | 2024-05-08 | Yale University | Compositions and methods for treating cancers |
| WO2023034864A1 (en) | 2021-08-31 | 2023-03-09 | Yale University | Compositions and methods for treating cancers |
| JP2026504180A (ja) | 2023-01-30 | 2026-02-03 | カイマブ・リミテッド | 抗体 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| DK2264043T3 (da) | 2005-09-02 | 2018-01-29 | Glycomimetics Inc | Heterobifunktionelle pan-selektin-inhibitorer |
| TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| WO2009126556A1 (en) | 2008-04-08 | 2009-10-15 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
| HUE065752T2 (hu) * | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| AU2010338305A1 (en) * | 2009-12-29 | 2012-05-24 | F. Hoffmann-La Roche Ag | Antibody formulation |
| US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
| CA2830806C (en) * | 2011-03-31 | 2020-05-12 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| KR101981873B1 (ko) * | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| AU2013212587B2 (en) | 2012-01-23 | 2017-07-20 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| SI3049441T1 (sl) | 2013-09-27 | 2020-03-31 | F. Hoffmann-La Roche Ag | Formulacije protiteles proti PD-L1 |
| WO2015057910A1 (en) * | 2013-10-16 | 2015-04-23 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| CN105085680A (zh) * | 2014-05-23 | 2015-11-25 | 复旦大学 | 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用 |
| CN112263677A (zh) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
| TW201705955A (zh) | 2015-05-14 | 2017-02-16 | 輝瑞大藥廠 | 包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法 |
| US20170000885A1 (en) | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| MY193229A (en) | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
| JP2018529719A (ja) | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ |
| DK3386541T3 (da) | 2015-12-07 | 2020-09-28 | Merck Patent Gmbh | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab |
| WO2018162446A1 (en) | 2017-03-06 | 2018-09-13 | Merck Patent Gmbh | Aqueous anti-pd-l1 antibody formulation |
-
2016
- 2016-12-05 DK DK16818985.0T patent/DK3386541T3/da active
- 2016-12-05 US US16/060,319 patent/US11058769B2/en active Active
- 2016-12-05 SM SM20200497T patent/SMT202000497T1/it unknown
- 2016-12-05 HU HUE16818985A patent/HUE050811T2/hu unknown
- 2016-12-05 AU AU2016368099A patent/AU2016368099C1/en active Active
- 2016-12-05 CA CA3007481A patent/CA3007481C/en active Active
- 2016-12-05 PL PL16818985T patent/PL3386541T3/pl unknown
- 2016-12-05 LT LTEP16818985.0T patent/LT3386541T/lt unknown
- 2016-12-05 JP JP2018529213A patent/JP6925337B2/ja active Active
- 2016-12-05 PE PE2018001077A patent/PE20181400A1/es unknown
- 2016-12-05 RS RS20201201A patent/RS61029B1/sr unknown
- 2016-12-05 SG SG11201804758QA patent/SG11201804758QA/en unknown
- 2016-12-05 EP EP16818985.0A patent/EP3386541B1/en active Active
- 2016-12-05 WO PCT/EP2016/002040 patent/WO2017097407A1/en not_active Ceased
- 2016-12-05 ES ES16818985T patent/ES2823279T3/es active Active
- 2016-12-05 NZ NZ743964A patent/NZ743964A/en unknown
- 2016-12-05 EA EA201891339A patent/EA201891339A1/ru unknown
- 2016-12-05 KR KR1020187019480A patent/KR102697026B1/ko active Active
- 2016-12-05 HR HRP20201573TT patent/HRP20201573T1/hr unknown
- 2016-12-05 MX MX2018006875A patent/MX389289B/es unknown
- 2016-12-05 UA UAA201807363A patent/UA123270C2/uk unknown
- 2016-12-05 PT PT168189850T patent/PT3386541T/pt unknown
- 2016-12-05 SI SI201630940T patent/SI3386541T1/sl unknown
- 2016-12-05 CN CN201680071740.1A patent/CN108367072B/zh active Active
- 2016-12-05 MY MYPI2018702171A patent/MY195681A/en unknown
- 2016-12-05 EP EP20184113.7A patent/EP3747466A1/en not_active Withdrawn
- 2016-12-06 TW TW105140288A patent/TWI630917B/zh active
- 2016-12-07 AR ARP160103760A patent/AR107014A1/es not_active Application Discontinuation
-
2018
- 2018-04-26 PH PH12018500894A patent/PH12018500894A1/en unknown
- 2018-05-23 IL IL259563A patent/IL259563B/en active IP Right Grant
- 2018-05-25 CO CONC2018/0005525A patent/CO2018005525A2/es unknown
- 2018-06-04 CL CL2018001488A patent/CL2018001488A1/es unknown
- 2018-06-06 SA SA518391743A patent/SA518391743B1/ar unknown
- 2018-07-06 ZA ZA201804534A patent/ZA201804534B/en unknown
-
2020
- 2020-09-24 CY CY20201100904T patent/CY1123358T1/el unknown
- 2020-12-09 US US17/116,587 patent/US20210100903A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3386541T3 (da) | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab | |
| IL282304A (en) | Topical pharmaceutical compositions | |
| FR25C1022I1 (fr) | Anticorps anti-pd-1 | |
| JP2018536676A5 (ja) | 抗ｐｄ−ｌ１抗体アベルマブを含む水性医薬製剤 | |
| EP3334824A4 (en) | PD-1 ANTIBODY | |
| PT4070788T (pt) | Formulações farmacêuticas | |
| EP3383915A4 (en) | PD-1 ANTIBODY | |
| DK3199161T3 (da) | Farmaceutisk præparat | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| EP3603642A4 (en) | PHARMACEUTICAL PREPARATION | |
| DK3256154T5 (da) | Farmaceutisk formulering omfattende antistof | |
| EP3383371C0 (en) | PHARMACEUTICAL FORMULATION | |
| EP3646866A4 (en) | PHARMACEUTICAL PREPARATION | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| EP3337463A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| HUE069648T2 (hu) | Gyógyszerészeti készítmény | |
| EP3498839A4 (en) | ANTI-PD-1 ANTIBODY | |
| DK3463365T3 (da) | Farmaceutisk antifungal formulering | |
| DK3247394T3 (da) | Farmaceutisk formulering omfattende anti-egfr-antistof | |
| EP3305294A4 (en) | AQUEOUS MEDICINE | |
| DK3601277T3 (da) | Farmaceutisk formulering | |
| DK3288967T3 (da) | Farmaceutisk forbindelse | |
| HUE050881T2 (hu) | Gyógyszerkészítmény | |
| EP3305295A4 (en) | AQUEOUS MEDICINE |